Cargando…

The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation

INTRODUCTION: The treatment of septic conditions in critically ill patients is still one of medicine's major challenges. Cyclic nucleotides, adenosine and its receptors play a pivotal role in the regulation of inflammatory responses and in limiting inflammatory tissue destruction. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayhan, Nalan, Funke, Benjamin, Conzelmann, Lars Oliver, Winkler, Harald, Hofer, Stefan, Steppan, Jochen, Schmidt, Heinfried, Bardenheuer, Hubert, Vahl, Christian-Friedrich, Weigand, Markus A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592762/
https://www.ncbi.nlm.nih.gov/pubmed/18847498
http://dx.doi.org/10.1186/cc7033
_version_ 1782161575112605696
author Kayhan, Nalan
Funke, Benjamin
Conzelmann, Lars Oliver
Winkler, Harald
Hofer, Stefan
Steppan, Jochen
Schmidt, Heinfried
Bardenheuer, Hubert
Vahl, Christian-Friedrich
Weigand, Markus A
author_facet Kayhan, Nalan
Funke, Benjamin
Conzelmann, Lars Oliver
Winkler, Harald
Hofer, Stefan
Steppan, Jochen
Schmidt, Heinfried
Bardenheuer, Hubert
Vahl, Christian-Friedrich
Weigand, Markus A
author_sort Kayhan, Nalan
collection PubMed
description INTRODUCTION: The treatment of septic conditions in critically ill patients is still one of medicine's major challenges. Cyclic nucleotides, adenosine and its receptors play a pivotal role in the regulation of inflammatory responses and in limiting inflammatory tissue destruction. The aim of this study was to verify the hypothesis that adenosine deaminase-1 and cyclic guanosine monophosphate-stimulated phosphodiesterase inhibition by erythro-9-[2-hydroxyl-3-nonyl]-adenine could be beneficial in experimental endotoxicosis/sepsis. METHOD: We used two established animal models for endotoxicosis and sepsis. Twenty-four male Wistar rats that had been given intravenous endotoxin (Escherichia coli lipopolysaccharide) were treated with either erythro-9-[2-hydroxyl-3-nonyl]-adenine infusion or 0.9% saline during a study length of 120 minutes. Sepsis in 84 female C57BL/6 mice was induced by caecal ligation and puncture. Animals were treated with repeated erythro-9-[2-hydroxyl-3-nonyl]-adenine injections after 0, 12 and 24 hours or 4, 12 and 24 hours for delayed treatment. RESULTS: In endotoxaemic rats, intestinal production of hypoxanthine increased from 9.8 +/- 90.2 μmol/l at baseline to 411.4 +/- 124.6 μmol/l and uric acid formation increased from 1.5 +/- 2.3 mmol/l to 13.1 +/- 2.7 mmol/l after 120 minutes. In endotoxaemic animals treated with erythro-9-[2-hydroxyl-3-nonyl]-adenine, we found no elevation of adenosine metabolites. The lactulose/L-rhamnose ratio (14.3 versus 4.2 in control animals; p = 2.5 × 10(-7)) reflects a highly permeable small intestine and through the application of erythro-9-[2-hydroxyl-3-nonyl]-adenine, intestinal permeability could be re-established. The lipopolysaccharide animals had decreased L-rhamnose/3-O-methyl-D-glucose urine excretion ratios. Erythro-9-[2-hydroxyl-3-nonyl]-adenine reduced this effect. The mucosa damage score of the septic animals was higher compared with control and therapy animals (p < 0.05). Septic shock induction by caecal ligation and puncture resulted in a 160-hour survival rate of about 25%. In contrast, direct adenosine deaminase-1 inhibition resulted in a survival rate of about 75% (p = 0.0018). A protective effect was still present when erythro-9-[2-hydroxyl-3-nonyl]-adenine treatment was delayed for four hours (55%, p = 0.029). CONCLUSIONS: We present further evidence of the beneficial effects achieved by administering erythro-9-[2-hydroxyl-3-nonyl]-adenine, an adenosine deaminase-1 and cyclic guanosine monophosphate-stimulated phosphodiesterase inhibitor, in an endotoxicosis and sepsis animal model. This suggests a potential therapeutic option in the treatment of septic conditions.
format Text
id pubmed-2592762
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25927622008-12-03 The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation Kayhan, Nalan Funke, Benjamin Conzelmann, Lars Oliver Winkler, Harald Hofer, Stefan Steppan, Jochen Schmidt, Heinfried Bardenheuer, Hubert Vahl, Christian-Friedrich Weigand, Markus A Crit Care Research INTRODUCTION: The treatment of septic conditions in critically ill patients is still one of medicine's major challenges. Cyclic nucleotides, adenosine and its receptors play a pivotal role in the regulation of inflammatory responses and in limiting inflammatory tissue destruction. The aim of this study was to verify the hypothesis that adenosine deaminase-1 and cyclic guanosine monophosphate-stimulated phosphodiesterase inhibition by erythro-9-[2-hydroxyl-3-nonyl]-adenine could be beneficial in experimental endotoxicosis/sepsis. METHOD: We used two established animal models for endotoxicosis and sepsis. Twenty-four male Wistar rats that had been given intravenous endotoxin (Escherichia coli lipopolysaccharide) were treated with either erythro-9-[2-hydroxyl-3-nonyl]-adenine infusion or 0.9% saline during a study length of 120 minutes. Sepsis in 84 female C57BL/6 mice was induced by caecal ligation and puncture. Animals were treated with repeated erythro-9-[2-hydroxyl-3-nonyl]-adenine injections after 0, 12 and 24 hours or 4, 12 and 24 hours for delayed treatment. RESULTS: In endotoxaemic rats, intestinal production of hypoxanthine increased from 9.8 +/- 90.2 μmol/l at baseline to 411.4 +/- 124.6 μmol/l and uric acid formation increased from 1.5 +/- 2.3 mmol/l to 13.1 +/- 2.7 mmol/l after 120 minutes. In endotoxaemic animals treated with erythro-9-[2-hydroxyl-3-nonyl]-adenine, we found no elevation of adenosine metabolites. The lactulose/L-rhamnose ratio (14.3 versus 4.2 in control animals; p = 2.5 × 10(-7)) reflects a highly permeable small intestine and through the application of erythro-9-[2-hydroxyl-3-nonyl]-adenine, intestinal permeability could be re-established. The lipopolysaccharide animals had decreased L-rhamnose/3-O-methyl-D-glucose urine excretion ratios. Erythro-9-[2-hydroxyl-3-nonyl]-adenine reduced this effect. The mucosa damage score of the septic animals was higher compared with control and therapy animals (p < 0.05). Septic shock induction by caecal ligation and puncture resulted in a 160-hour survival rate of about 25%. In contrast, direct adenosine deaminase-1 inhibition resulted in a survival rate of about 75% (p = 0.0018). A protective effect was still present when erythro-9-[2-hydroxyl-3-nonyl]-adenine treatment was delayed for four hours (55%, p = 0.029). CONCLUSIONS: We present further evidence of the beneficial effects achieved by administering erythro-9-[2-hydroxyl-3-nonyl]-adenine, an adenosine deaminase-1 and cyclic guanosine monophosphate-stimulated phosphodiesterase inhibitor, in an endotoxicosis and sepsis animal model. This suggests a potential therapeutic option in the treatment of septic conditions. BioMed Central 2008 2008-10-13 /pmc/articles/PMC2592762/ /pubmed/18847498 http://dx.doi.org/10.1186/cc7033 Text en Copyright © 2008 Kayhan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kayhan, Nalan
Funke, Benjamin
Conzelmann, Lars Oliver
Winkler, Harald
Hofer, Stefan
Steppan, Jochen
Schmidt, Heinfried
Bardenheuer, Hubert
Vahl, Christian-Friedrich
Weigand, Markus A
The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
title The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
title_full The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
title_fullStr The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
title_full_unstemmed The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
title_short The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
title_sort adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592762/
https://www.ncbi.nlm.nih.gov/pubmed/18847498
http://dx.doi.org/10.1186/cc7033
work_keys_str_mv AT kayhannalan theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT funkebenjamin theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT conzelmannlarsoliver theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT winklerharald theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT hoferstefan theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT steppanjochen theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT schmidtheinfried theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT bardenheuerhubert theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT vahlchristianfriedrich theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT weigandmarkusa theadenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT kayhannalan adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT funkebenjamin adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT conzelmannlarsoliver adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT winklerharald adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT hoferstefan adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT steppanjochen adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT schmidtheinfried adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT bardenheuerhubert adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT vahlchristianfriedrich adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation
AT weigandmarkusa adenosinedeaminaseinhibitorerythro92hydroxyl3nonyladeninedecreasesintestinalpermeabilityandprotectsagainstexperimentalsepsisaprospectiverandomisedlaboratoryinvestigation